

2. (Amended) A method for treating ribavirin or ribavirin and interferon-alpha induced anemia in hepatitis C patients comprising administering erythropoietin to a patient in need thereof as a liquid preparation subcutaneously, parenterally, intradermally, intramuscularly or intravenously.

3. (Amended) A method for treating ribavirin or [ribivirn] ribavirin and interferon-alpha induced anemia comprising administering Erythropoietin to a patient in need thereof as a suspension, emulsion, syrup or elixir.

4. (Amended) A method for treating hepatitis C (HCV) and for treating ribavirin or [ribivirn] ribavirin and interferon-alpha induced anemia employed in treating said HCV in a patient in need thereof by administering erythropoietin to the patient subcutaneously for at least about six months.

5. (Amended) A method for treating hepatitis C (HCV) and for treating ribavirin or [ribivirn] ribavirin and interferon-alpha induced anemia employed in treating said HCV in a patient in need thereof by administering erythropoietin to the patient subcutaneously for at least about 12 months.

7. (Amended) The method of claim 5 wherein the hepatitis C is genotype 1 and/or 4.

12. (Amended) The method of claim 9 wherein the patient is HIV positive
having genotype 2 and/or 3 hepatitis C.

Q1

Please cancel claims 13 to 16 without prejudice, without admission, without
surrender of subject matter, and without any intention to create any estoppel as to equivalents.
